WallStSmart

Abbott Laboratories (ABT)vsBluejay Diagnostics Inc (BJDX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ABT leads profitability with a 13.9% profit margin vs 0.0%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

BJDX

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: -7.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued

Intrinsic value data unavailable for BJDX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

BJDX2 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

BJDX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.49M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : BJDX

The strongest argument for BJDX centers on Price/Book, Debt/Equity.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : BJDX

The primary concerns for BJDX are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

BJDX carries more volatility with a beta of 0.72 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (56/100 vs 26/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Bluejay Diagnostics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Bluejay Diagnostics Inc. is an innovative medical technology firm focused on advancing patient care through cutting-edge diagnostic solutions aimed at early disease detection. Leveraging a proprietary platform that combines artificial intelligence with point-of-care testing, the company enhances diagnostic accuracy and speed, providing healthcare professionals with timely and actionable insights. With a robust commitment to research and development, Bluejay is adeptly positioned to fill significant healthcare gaps and cater to the growing demand for trustworthy and innovative diagnostic tools in a rapidly changing medical landscape.

Visit Website →

Want to dig deeper into these stocks?